Prelude Therapeutics (PRLD) Beats Q4 Earnings Estimates by $0.04
Prelude Therapeutics (NASDAQ:PRLD) reported quarterly earnings results on March 10, 2026 that exceeded analyst expectations. The Healthcare company reported earnings per share of…
Read more
